STOCK TITAN

Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Foghorn Therapeutics (Nasdaq: FHTX) announced a full clinical hold by the FDA on the Phase 1 study of its drug FHD-286 for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). This decision arose from reports of additional suspected fatal differentiation syndrome cases linked to FHD-286. Meanwhile, the study for metastatic uveal melanoma is proceeding as planned, with data expected in early 2023. Foghorn remains committed to addressing FDA concerns to lift the hold promptly.

Positive
  • The clinical study of FHD-286 for metastatic uveal melanoma continues as planned.
  • Data from the ongoing study is set to be reported in the first half of 2023.
Negative
  • The FDA placed a full clinical hold on the AML/MDS study due to safety concerns.
  • Reports of additional suspected fatal differentiation syndrome may hinder the drug's development.
  • FDA requires further analyses before the hold can be lifted.

CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on the Phase 1 dose escalation study of FHD-286, an inhibitor of BRG1/BRM, in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The dose escalation Phase 1 study of FHD-286 in metastatic uveal melanoma (mUM) continues per protocol. The company plans to report data from the mUM study in the first half of 2023.

The full clinical hold in the AML/MDS study is due to the observation, in the data submitted in response to the partial hold, of additional suspected cases of fatal differentiation syndrome believed to be associated with FHD-286. Differentiation syndrome is associated with AML/MDS therapeutics that induce differentiation, an effect that has been seen with, and is believed to be on-target for, the proposed mechanism of action for FHD-286. The FDA has additional questions and requires further analyses before the clinical hold may be lifted.

“We are committed to patient safety and will work with the FDA to address the agency’s questions and provide further analyses to resolve the clinical hold as soon as possible,” said Foghorn CEO Adrian Gottschalk.

About FHD-286

FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, two highly similar proteins that are the ATPases, or the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors. To learn more about these studies please visit ClinicalTrials.gov. (Link here for metastatic uveal melanoma and here for AML and MDS).

About AML

Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and the most common type of acute leukemia in adults. AML is a diverse disease associated with multiple genetic mutations. It is diagnosed in about 20,000 people every year in the United States.

About Uveal Melanoma

Uveal (intraocular) melanoma (UM) is a rare eye cancer that forms from cells that make melanin in the iris, ciliary body, and choroid. It is the most common eye cancer in adults. It is diagnosed in about 2,000 adults every year in the United States and occurs most often in lightly pigmented individuals with a median age of 55 years. However, it can occur in all races and at any age. UM metastasizes in approximately 50% of cases, leading to very poor prognosis.

About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the company, and follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements concerning the Company’s clinical trials, including the Company’s efforts to resolve the full clinical hold relating to its Phase 1 clinical trial of FHD-286 in AML/MDS and the timing of release of initial clinical data relating to its ongoing clinical trials. Forward-looking statements include statements regarding the Company’s clinical trials, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Contact:

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com

Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com

Michael Lampe, ScientPR (Media)
michael@scientpr.com 

Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com


FAQ

What is the reason for the FDA's clinical hold on FHTX's FHD-286?

The FDA placed a full clinical hold on the Phase 1 study of FHD-286 due to additional suspected cases of fatal differentiation syndrome.

Is the clinical hold affecting all studies of FHD-286?

No, only the Phase 1 dose escalation study for AML/MDS is on hold; the study for metastatic uveal melanoma continues.

When can we expect data from the ongoing FHD-286 study?

Foghorn plans to report data from the metastatic uveal melanoma study in the first half of 2023.

What does the differentiation syndrome associated with FHD-286 mean for patients?

Differentiation syndrome is a serious condition that can occur with AML/MDS therapies, potentially leading to fatal outcomes.

What is FHTX's commitment following the FDA's clinical hold?

Foghorn is committed to patient safety and will work with the FDA to address concerns and resolve the clinical hold as soon as possible.

Foghorn Therapeutics Inc.

NASDAQ:FHTX

FHTX Rankings

FHTX Latest News

FHTX Stock Data

280.19M
44.98M
18.98%
72.11%
1.77%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE